Pear Therapeutics, Inc. Stock

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.